Hoe verhoudt TNDM's PS Ratio zich tot zijn concurrenten?

TNDM is een goede waarde op basis van zijn Price-To-Sales Ratio (2.4x) vergeleken met het gemiddelde van gelijken (2.4x).

Hoe verhoudt TNDM's PS Ratio zich tot andere bedrijven in de US Medical Equipment industrie?

TNDM is een goede waarde op basis van de Price-To-Sales -ratio ( 2.4 x) vergeleken met het US Medical Equipment -industriegemiddelde ( 3.3 x).

Wat is TNDM's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

TNDM is duur op basis van de Price-To-Sales Ratio ( 2.4 x) vergeleken met de geschatte Fair Price-To-Sales Ratio ( 1.9 x).

Wat is de reële prijs van TNDM als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

TNDM ( $30.81 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $83.05 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling ligt meer dan 20 % hoger dan de huidige aandelenkoers, maar analisten zijn het statistisch gezien niet eens over de overeengekomen marge.

Tandem Diabetes Care (Nasdaq:TNDM) - Aandelenkoers, Nieuws & Analyse

TNDM Overzicht aandelen

TNDM fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 62.9% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 10.31% per jaar groeien

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Tandem Diabetes Care, Inc. Concurrenten

NuVasive

NasdaqGS:NUVA

US$2.1b

Omnicell

NasdaqGS:OMCL

US$2.1b

NovoCure

NasdaqGS:NVCR

US$1.9b

CONMED

NYSE:CNMD

US$2.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Tandem Diabetes Care
Historische aandelenkoersen
Huidige aandelenkoers	US$30.81
52 Week Hoogtepunt	US$53.69
52 Week Laag	US$18.45
Bèta	1.37
11 maand verandering	-1.72%
3 maanden verandering	-32.39%
1 Jaar Verandering	58.24%
33 jaar verandering	-76.42%
5 jaar verandering	-54.31%
Verandering sinds IPO	-84.00%

Recent nieuws en updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Nov 16

Recent updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Nov 16

Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?

Sep 28

Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk

Aug 31

Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin

Aug 14

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 04

Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Jul 12

Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?

Jun 18

Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here

May 29

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors

May 10

A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

May 04

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Mar 26

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Mar 08

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Feb 22

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jan 14

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Dec 27

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Nov 12

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Oct 06

Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Sep 17

Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Aug 08

Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jul 03

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Jun 13

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

May 06

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Jan 04

Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?

Oct 15

Tandem Diabetes Care: Overpriced, Underdelivering

Sep 22

An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued

Sep 10

Tandem Diabetes stock falls 10% on disappointing Q2 result

Aug 03

Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed

Jul 21

Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings

Jul 08

Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital

Jun 20

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price

May 30

Rendement voor aandeelhouders

	TNDM	US Medical Equipment	US Markt
7D	7.1%	1.5%	2.2%
1Y	58.2%	20.8%	31.6%

Rendement versus industrie: TNDM overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 20.8 % opleverde.

Rendement versus markt: TNDM overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.6 %.

Prijsvolatiliteit

Is TNDM's price volatile compared to industry and market?
TNDM volatility
TNDM Average Weekly Movement	7.0%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: TNDM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van TNDM is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	2,400	John Sheridan	www.tandemdiabetes.com

Tandem Diabetes Care, Inc. is een bedrijf voor medische hulpmiddelen en ontwerpt, ontwikkelt en verkoopt technologische oplossingen voor mensen met diabetes in de Verenigde Staten en daarbuiten. Het paradepaardje van het bedrijf is het t:slim X2-systeem voor insulinetoediening, een pompplatform voor het beheer van de insulinetoediening en de weergave van sensorinformatie voor continue glucosemonitoring rechtstreeks op het startscherm van de pomp; en de Tandem Mobi-insulinepomp, een geautomatiseerd systeem voor insulinetoediening. Het bedrijf verkoopt ook producten voor eenmalig gebruik, waaronder cartridges voor het opslaan en toedienen van insuline en infusiesets die de insulinepomp verbinden met het lichaam van de gebruiker.

Tandem Diabetes Care, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Tandem Diabetes Care zich tot de beurswaarde?
TNDM fundamentele statistieken
Marktkapitalisatie	US$2.02b
Inkomsten(TTM)	-US$126.78m
Inkomsten(TTM)	US$854.35m

2.4x

P/S-verhouding

-16.0x

Koers/Winstverhouding

Is TNDM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TNDM resultatenrekening (TTM)
Inkomsten	US$854.35m
Kosten van inkomsten	US$428.94m
Brutowinst	US$425.41m
Overige uitgaven	US$552.20m
Inkomsten	-US$126.78m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.93
Brutomarge	49.79%
Nettowinstmarge	-14.84%
Schuld/Eigen Vermogen Verhouding	146.6%

Hoe presteerde TNDM op de lange termijn?

Bekijk historische prestaties en vergelijking

TNDM Overzicht aandelen

Beloningen

Risicoanalyse

Tandem Diabetes Care, Inc. Concurrenten

NasdaqGS:NUVA

US$2.1b

NasdaqGS:OMCL

US$2.1b

NasdaqGS:NVCR

US$1.9b

NYSE:CNMD

US$2.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Tandem Diabetes Care, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?

Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin

Recent updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Tandem Diabetes Care, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?

Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Tandem Diabetes Care, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell 3000E Value Index

Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024

Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?

Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here

President exercised options and sold US$503k worth of stock

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors

A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.8% to US$37.36

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Consensus EPS estimates fall by 31%

Now 21% undervalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Price target increased by 10.0% to US$31.67

Now 23% undervalued

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 26% to US$29.73

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Price target decreased by 7.3% to US$37.80

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Now 23% undervalued after recent price drop

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Price target decreased by 8.8% to US$46.07

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Independent Director recently bought US$295k worth of stock

Executive VP recently bought US$99k worth of stock

Consensus EPS estimates fall by 127%

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

First quarter 2023 earnings: EPS misses analyst expectations

Executive VP & COO notifies of intention to sell stock

Price target decreased by 8.1% to US$54.38

Full year 2022 earnings: EPS misses analyst expectations

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .